ISG15 and melanoma: Remarkably, the dominance of individual regulatory ISGs in restricting ADU-S100 therapy benefits varied between the B16 and BPR20 melanoma models, with anti-PD-L1 and anti-ISG15 (but not ARG2i/COX2i/NOS2i) preferentially improving the therapeutic efficacy of STING agonist in the B16 (BRAFWTPTENWT) melanoma model.